NCT00426712 - Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Hepatitis B

Interventions

BIOLOGICAL

1018 ISS immunostimulatory oligonucleotide with HBV surface antigen

Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8

BIOLOGICAL

Hepatitis B Vaccine (Recombinant)

IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24

Trial Locations (4)

University of Virginia Health System, Nephrology Clinical Research Center, Charlottesville

Twin Cities Clinical Research, Brooklyn Center

Covance, Austin

West Coast Clinical Trials, Costa Mesa